Letter to the Editor: Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial

In this study, there was a selection bias attributable to the inclusion of eyes that had received various treatments before enrollment, namely focal laser therapy (FLT), panretinal photocoagulation (PRP), and intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA). Moreover, this study allowed for the inclusion of eyes with epiretinal membranes (ERMs) and vitreomacular adhesions (VMAs) per investigator discretion.The following

Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - March 21, 2018 Category: Opthalmology Authors: Dan C ălugăru, MD, PhD Source Type: research